Cagrilintide
Cagrilintide is an investigational long-acting analogue of the pancreatic hormone amylin, studied for weight management on its own and combined with semaglutide.
Regulatory status: Investigational. Cagrilintide, alone and as the co-formulation with semaglutide, is in phase 3 trials and has no FDA or other regulatory approval.
Default vial
5 mg
Default mix
2 mL
Reported range
0.3 → 2.4 mg
Draw (U-100)
12 u
Long-acting amylin analog, weekly. Often paired with a GLP-1 — stack cautiously and titrate one compound at a time.
What it is
- An amylin receptor agonist: a long-acting, acylated analogue of the pancreatic hormone amylin.
- A peptide hormone analogue whose mechanism is distinct from — and studied as complementary to — GLP-1 agonists.
- Given once weekly by subcutaneous injection, with phase 2 dose-finding up to 4.5 mg.
- Studied both as monotherapy and combined with semaglutide.
How it is described to act
- 1
Administered subcutaneously in trial settings, absorbed slowly in keeping with weekly dosing.
- 2
Reported to reach tissues expressing amylin receptors, including the area postrema and other central satiety regions.
- 3
Proposed to act at amylin receptors, slowing gastric emptying and promoting satiety by a route separate from GLP-1 signalling.
- 4
In trial cohorts, alone or with semaglutide, this was associated with reduced body weight, with the combination reported to exceed either agent alone.
What the research has looked at
Phase 2 monotherapy
- In a multicentre randomised dose-finding phase 2 trial (Lancet, 2021), Lau et al. reported significantly greater weight loss with once-weekly cagrilintide than placebo over 26 weeks in people with overweight or obesity.
Combination with semaglutide
- A 2025 randomised trial in adults with overweight or obesity and type 2 diabetes reported outcomes for combined cagrilintide-semaglutide therapy against the individual components.
Strength of evidence: Limited human evidence
Published phase 2 randomised data and ongoing phase 3 trials exist, but no completed regulatory review.
Some human data exist, but they are small, short, or not designed to answer the questions people ask online.
Reported cautions and unknowns
- Nausea, vomiting and constipation were the most common adverse events in the phase 2 monotherapy trial, mostly mild to moderate and more frequent at higher doses.
- Injection-site reactions were reported in that trial.
- As an investigational agent, long-term pancreatitis, thyroid, gallbladder and pregnancy safety have not been fully characterised.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
Cagrilintide questions people ask
How do you reconstitute Cagrilintide?
A common starting point for a 5 mg vial of Cagrilintide is 2 mL of bacteriostatic water, which gives 2.5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of Cagrilintide is one dose?
At 2.5 mg per mL, that works out to about 12 units on a U-100 insulin syringe for a 300 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for Cagrilintide?
Published and community sources describe 0.3 → 2.4 mg, subcutaneous, once weekly, typically run 16 weeks on. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should Cagrilintide be stored?
Lyophilized Cagrilintide vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.